Skip to main content
Signal8
Launch Terminal

PROCEPT BioRobotics Corp (PRCT)

PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.

Sector: Surgical & Medical Instruments & Apparatus

Industry: Medical - Devices

PROCEPT BioRobotics Corporation logo

PROCEPT BioRobotics Corporation

NASDAQ:PRCTHealthcare
-5.42%$19.20
AH$19.20+0.00%vs close
Mkt Cap$1.1B
Float53.23M
O/S57.27M
Vol
$ Vol
RVOL
Inst Own93.0%
SI14.1%
Earnings
Dilution
PROCEPT BioRobotics Corporation logoNASDAQ:PRCT$19.20-5.42%
Phase Distribution
13 lead-sponsored trials·2 active·7 completed
Not applicable13
(3 more as collaborator)
Status Overview
Not yet recruiting1
Active, not recruiting2
Completed7
Unknown3

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
  • Not applicable
    Completed

    Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER)

    AQUABEAM System, Transurethral Resection of the Prostate (TURP)

    Benign Prostatic Hyperplasia (BPH)

    Enrollment
    184
    Start
    Oct 2015
    Primary Completion
    Jul 2017
    Completion
    Dec 2021
    NCT02505919
  • Observational
    Unknown status

    Global Post-Market Registry Using Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue

    Aquablation

    BPH

    Enrollment
    178
    Start
    Sep 2017
    Primary Completion
    May 2019
    Completion
    Feb 2020est.
    NCT02974751
  • Not applicable
    Completed

    Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II

    Aquablation

    Benign Prostatic Hyperplasia (BPH)

    Enrollment
    101
    Start
    Aug 2017
    Primary Completion
    Mar 2018
    Completion
    Dec 2022
    NCT03123250
  • Not applicable
    Completed

    Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia

    AquaBeam System

    Benign Prostatic Hyperplasia

    Enrollment
    21
    Start
    Aug 2016
    Primary Completion
    Sep 2016
    Completion
    Jul 2017
    NCT03125863
  • Not applicable
    Completed

    Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia II

    AquaBeam System

    Benign Prostatic Hyperplasia

    Enrollment
    11
    Start
    Apr 2017
    Primary Completion
    Apr 2017
    Completion
    Jul 2017
    NCT03125889
  • Not applicable
    Completed

    AQUABEAM India Study for the Treatment of Benign Prostatic Hyperplasia

    AquaBeam System

    Benign Prostatic Hyperplasia

    Enrollment
    47
    Start
    Dec 2014
    Primary Completion
    Jun 2016
    Completion
    Apr 2017
    NCT03167294
  • Not applicable
    Completed

    French Aquablation Clinical Investigation Using Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue

    AQUABEAM System

    Benign Prostatic Hyperplasia (BPH)

    Enrollment
    30
    Start
    Sep 2017
    Primary Completion
    Jul 2018
    Completion
    Jan 2019
    NCT03191734
  • Not applicable
    Completed

    Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia III

    AQUABEAM System followed by catheter without hemostatic agent, AQUABEAM System followed by catheter with hemostatic agent

    Benign Prostatic Hyperplasia

    Enrollment
    26
    Start
    Jul 2017
    Primary Completion
    Mar 2018
    Completion
    Jun 2018
    NCT04308070
  • Observational
    Unknown status

    UK Post-market Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue

    -

    Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms

    Enrollment
    46
    Start
    Jan 2021est.
    Primary Completion
    Jan 2022est.
    Completion
    Feb 2022est.
    NCT04658056
  • Not applicable
    Active, not recruiting

    PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs

    Robotic Waterjet Treatment

    Benign Prostatic Hyperplasia, Localized Prostate Cancer

    Enrollment
    125
    Start
    Nov 2022
    Primary Completion
    Jul 2026est.
    Completion
    Mar 2027est.
    NCT06051942
  • Not applicable
    Unknown status

    PRCT002 PRostate Cancer Treatment With the AQUABEAM Robotic System

    Robotic Waterjet Treatment

    Localized Prostate Cancer

    Enrollment
    22
    Start
    Mar 2024
    Primary Completion
    Apr 2025est.
    Completion
    Apr 2025est.
    NCT06054867
  • Not applicable
    Active, not recruiting

    WATER IV Prostate Cancer

    Aquablation Therapy, Radical Prostatectomy

    Localized Prostate Cancer

    Enrollment
    280
    Start
    Feb 2025
    Primary Completion
    Jul 2027est.
    Completion
    Jan 2037est.
    NCT06651632
  • Not applicable
    Not yet recruiting

    WATER IV PCa (AS Sub-study)

    Aquablation Therapy, Active Surveillance

    Localized Prostate Cancer

    Enrollment
    333
    Start
    Sep 2026est.
    Primary Completion
    Dec 2028est.
    Completion
    Dec 2038est.
    NCT07650448
Search ClinicalTrials.gov for “PROCEPT BioRobotics”